Alterome Therapeutics schedules first Phase 1 clinical data presentation for pan-KRAS inhibitor ALTA3263
Alterome Therapeutics will reveal first ALTA3263 Phase 1 data in November, testing the safety and early activity of its oral pan-KRAS inhibitor.
Pharma & Biotech
Medical Devices & Diagnostics
Intus Biosciences gets $2.7m NCI award for microbiome-based early-onset colorectal cancer test
NCI awards Intus Bio $2.7 million to develop a microbiome-based test for early-onset colorectal cancer and precancerous lesions.
Pharma & Biotech
Actinium expands Actimab-A intellectual property as Actinium-225 manufacturing becomes a strategic priority
Actinium advances Actimab-A IP and manufacturing while NYSE American compliance adds a parallel financing and execution test.
Pharma & Biotech
Bria-PROS+ moves into Phase 1/2a testing with FDA clearance in prostate cancer
FDA clearance allows Bria-PROS+ to enter Phase 1/2a prostate cancer testing. Read how the off-the-shelf cellular immunotherapy works.
Medical Devices & Diagnostics
Can Invenio Imaging’s AI deliver reliable lung biopsy feedback inside the bronchoscopy room?
Invenio Imaging completes ON-SITE enrolment as NIO Lung Cancer Reveal moves toward pivotal analysis and a potential FDA submission.
Medical Devices & Diagnostics
How the Teal Health UC Davis pilot could reshape cervical cancer screening workflows
Teal Health and UC Davis Health test how FDA-authorized at-home HPV screening can fit routine care and reach overdue patients.
Pharma & Biotech
Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment
Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.
Pharma & Biotech
Why ImmunityBio’s Japan BCG Laboratory agreement matters beyond bladder cancer supply
A bladder cancer supply crisis meets fresh Phase III data. ImmunityBio’s Tokyo BCG deal could test how flexible U.S. regulators are willing to be.